Catalyst Pharmaceuticals (NASDAQ:CPRX) Raised to Strong-Buy at StockNews.com

Catalyst Pharmaceuticals (NASDAQ:CPRX) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Friday.

Several other equities analysts have also recently commented on CPRX. Baird R W upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Bank of America restated a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Robert W. Baird assumed coverage on shares of Catalyst Pharmaceuticals in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $28.00 target price for the company. Stephens restated an “overweight” rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday. Finally, Truist Financial boosted their target price on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $32.00.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock opened at $22.89 on Friday. The company has a market capitalization of $2.73 billion, a price-to-earnings ratio of 19.40, a PEG ratio of 3.31 and a beta of 0.80. The company has a 50-day simple moving average of $22.24 and a 200 day simple moving average of $21.43. Catalyst Pharmaceuticals has a 52 week low of $14.47 and a 52 week high of $24.64.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the completion of the transaction, the insider now directly owns 686,996 shares in the company, valued at approximately $15,065,822.28. This represents a 6.78 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 11.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in CPRX. Creative Planning increased its position in Catalyst Pharmaceuticals by 26.9% in the 3rd quarter. Creative Planning now owns 12,724 shares of the biopharmaceutical company’s stock valued at $253,000 after acquiring an additional 2,699 shares during the period. Wealth Enhancement Advisory Services LLC increased its position in Catalyst Pharmaceuticals by 11.0% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 20,017 shares of the biopharmaceutical company’s stock valued at $398,000 after acquiring an additional 1,989 shares during the period. DekaBank Deutsche Girozentrale increased its position in shares of Catalyst Pharmaceuticals by 48.6% during the third quarter. DekaBank Deutsche Girozentrale now owns 183,376 shares of the biopharmaceutical company’s stock worth $3,532,000 after buying an additional 60,000 shares during the period. Summit Global Investments increased its position in shares of Catalyst Pharmaceuticals by 2.6% during the third quarter. Summit Global Investments now owns 77,292 shares of the biopharmaceutical company’s stock worth $1,537,000 after buying an additional 1,923 shares during the period. Finally, CWA Asset Management Group LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the third quarter worth $534,000. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.